AZD7503 for Non-alcoholic Fatty Liver Disease

"This new treatment has yet to be fully assessed, so its safety is estimated at a score of 1. As this is just a Phase 1 trial, there are only limited data points that support both efficacy and safety."

"This clinical trial is designed for individuals aged 18 to 75, however there are 19 studies open for minors and 206 specific to elderly patients."

"At present, 10 different clinical sites are running this trial. These clinics can be found in Hialeah, Port Orange and San Juan as well as other cities throughout the country. It is important to select a nearby clinic should you join the study so that travel requirements are kept at a minimum."

"Affirmative. According to the information hosted on clinicaltrials.gov, this trial is currently enrolling participants; it was first advertised in March of 2023 and was most recently updated last month in May. The study requires 60 individuals across 10 sites for recruitment."

"Affirmative, according to the information on clinicaltrials.gov this investigation is actively recruiting volunteers. The trial was first announced on March 31st 2023 and has been recently updated on May 25th 2023. 60 individuals are required from 10 different medical centres."

"Eligibility requirements to join this clinical trial are non-alcoholic fatty liver disease and an age between 18 and 75. The total number of participants being accepted is approximately 60 individuals."

"According to the trial sponsor, AstraZeneca, primary outcomes will be measured from pre-screening until final visit (up to 18 weeks). The number of subjects with adverse events (AEs) is one metric being tracked. Secondary outcome metrics include Area under the concentration-time curve from time 0 to infinity (AUCinf), Area under the concentration-time curve over the dosing interval (AUCtau), and Maximum observed plasma drug concentration (Cmax)."